Cargando…

A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol

BACKGROUND: Recent evidence underscores the utility of rapid-acting antidepressant interventions, such as ketamine, in alleviating symptoms of major depressive episodes (MDE). However, to date, there have been limited head-to-head comparisons of intravenous (IV) ketamine infusions with other antidep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Phillips, Jennifer L., Jaworska, Natalia, Kamler, Elizabeth, Bhat, Venkat, Blier, Jean, Foster, Jane A., Hassel, Stefanie, Ho, Keith, McMurray, Lisa, Milev, Roumen, Moazamigoudarzi, Zahra, Placenza, Franca M., Richard-Devantoy, Stéphane, Rotzinger, Susan, Turecki, Gustavo, Vazquez, Gustavo H., Kennedy, Sidney H., Blier, Pierre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265624/ https://www.ncbi.nlm.nih.gov/pubmed/32487236 http://dx.doi.org/10.1186/s12888-020-02672-3

Ejemplares similares

Prediction of depression treatment outcome from multimodal data: a CAN-BIND-1 report
por: Sajjadian, Mehri, et al.
Publicado: (2023)

Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study
por: Islam, Farhana, et al.
Publicado: (2022)

Intravenous ketamine for benzodiazepine deprescription and withdrawal management in treatment-resistant depression: a preliminary report
por: Garel, Nicolas, et al.
Publicado: (2023)

The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression
por: Garel, Nicolas, et al.
Publicado: (2023)

Developing an Electroencephalography-Based Model for Predicting Response to Antidepressant Medication
por: Schwartzmann, Benjamin, et al.
Publicado: (2023)

Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response
por: Fiori, Laura M, et al.
Publicado: (2017)

Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort
por: Lam, Raymond W., et al.
Publicado: (2016)

Metabolomic signatures associated with depression and predictors of antidepressant response in humans: A CAN-BIND-1 report
por: Caspani, Giorgia, et al.
Publicado: (2021)

Sex Differences in the Behavioral, Molecular, and Structural Effects of Ketamine Treatment in Depression
por: Ponton, Ethan, et al.
Publicado: (2021)

Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient
por: Oluboka, Oloruntoba J, et al.
Publicado: (2017)

Medical assistance in living after failure of ECT and ketamine
por: Lafrenière, Simon, et al.
Publicado: (2022)

“One Degree of Separation”: A Mixed-Methods Evaluation of Canadian Mental Health Care User and Provider Experiences With Remote Care During COVID-19
por: Ceniti, Amanda K., et al.
Publicado: (2022)

Does serotonin matter in depression?
por: Albert, Paul R., et al.
Publicado: (2023)

Effects of Electroconvulsive Therapy and Repetitive Transcranial Magnetic Stimulation on Serum Brain-Derived Neurotrophic Factor Levels in Patients with Depression
por: Gedge, Laura, et al.
Publicado: (2012)

Pre-treatment EEG signal variability is associated with treatment success in depression
por: Jaworska, Natalia, et al.
Publicado: (2017)

Response of Depression to Botulinum Toxin Treatment: Agitation as a Predictor
por: Milev, Roumen
Publicado: (2015)

Assessment of Objective and Subjective Cognitive Function in Patients With Treatment-Resistant Depression Undergoing Repeated Ketamine Infusions
por: Phillips, Jennifer L, et al.
Publicado: (2022)

A standardized workflow for long-term longitudinal actigraphy data processing using one year of continuous actigraphy from the CAN-BIND Wellness Monitoring Study
por: Slyepchenko, Anastasiya, et al.
Publicado: (2023)

Resting-state EEG delta and alpha power predict response to cognitive behavioral therapy in depression: a Canadian biomarker integration network for depression study
por: Schwartzmann, Benjamin, et al.
Publicado: (2023)

Comparison of efficacy of ketamine versus thiopentone-assisted modified electroconvulsive therapy in major depression
por: Jagtiani, Amit, et al.
Publicado: (2019)

Comparison of efficacy of ketamine versus thiopentone-assisted modified electroconvulsive therapy in major depression
por: Jagtiani, Amit, et al.
Publicado: (2020)

The noradrenergic paradox: implications in the management of depression and anxiety
por: Montoya, Alonso, et al.
Publicado: (2016)

Data mining EEG signals in depression for their diagnostic value
por: Mohammadi, Mahdi, et al.
Publicado: (2015)

Association between the expression of lncRNA BASP-AS1 and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 report
por: Yrondi, Antoine, et al.
Publicado: (2021)

Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy
por: Espinola, Caroline W., et al.
Publicado: (2022)

Comparative Effect of Intravenous Ketamine and Electroconvulsive Therapy in Major Depression: A Randomized Controlled Trial
por: Kheirabadi, Gholamreza, et al.
Publicado: (2019)

Effects of ketamine in electroconvulsive therapy for major depressive disorder: meta-analysis of randomised controlled trials
por: Li, Xiao-Mei, et al.
Publicado: (2020)

Olfactory Functioning and Depression: A Systematic Review
por: Taalman, Hannah, et al.
Publicado: (2017)

Ketamine promptly normalizes excess norepinephrine and enhances dopamine neuronal activity in Wistar Kyoto rats
por: Daniels, Stephen, et al.
Publicado: (2023)

Repeated but Not Single Administration of Ketamine Prolongs Increases of the Firing Activity of Norepinephrine and Dopamine Neurons
por: Iro, Chidiebere M, et al.
Publicado: (2021)

Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report
por: Yrondi, Antoine, et al.
Publicado: (2019)

The miRNome of Depression
por: Żurawek, Dariusz, et al.
Publicado: (2021)

Balance Problems, Paralysis, and Angina as Clinical Markers for Severity in Major Depression
por: Qi, Bill, et al.
Publicado: (2020)

Corrigendum to: Repeated but not Single Administration of Ketamine Prolongs Increases of the Firing Activity of Norepinephrine and Dopamine Neurons
por: Iro, Chidiebere M, et al.
Publicado: (2021)

Ketamine for Bipolar Depression: A Systematic Review
por: Bahji, Anees, et al.
Publicado: (2021)

The effects of probiotics on depressive symptoms in humans: a systematic review
por: Wallace, Caroline J. K., et al.
Publicado: (2017)

Antidepressant Effect of Combined Ketamine and Electroconvulsive Therapy on Patients With Major Depressive Disorder: A Randomized Trial
por: Shams Alizadeh, Narges, et al.
Publicado: (2015)

Ketamine Augmentation of Electroconvulsive Therapy: A Scoping Review of Dose-Dependent Effects in Major Depressive Disorder
por: Nagi, Tarika, et al.
Publicado: (2023)

Connectomics-Based Functional Network Alterations in both Depressed Patients with Suicidal Behavior and Healthy Relatives of Suicide Victims
por: Wagner, Gerd, et al.
Publicado: (2019)

Ketamine and Electroconvulsive Therapy: Better Together?
por: Fraga, A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ejeqea6jcig96m9c3vcema6155